Updated:
RBV Capital
RBV Capital is a EU-based life sciences venture fund. It invests in pharmaceuticals, biologics, digital healthcare products, and medical devices.
RBV Capital
RBV Capital is a EU-based life sciences venture fund. It invests in pharmaceuticals, biologics, digital healthcare products, and medical devices. The firm has made 7 investments, including a Seed VC in PanDx on December 28, 2020.
General information
Firm type
Private Equity
Year founded
2014
AUM
Undisclosed
Location
Region
Europe
Country
Russia
City
Moscow
Corporate office
Moscow, Russia
Frequently asked questions
Who leads RBV Capital's investment decisions?
Specific investment leadership is not identified in publicly available materials. RBV Capital discloses no named principals on its website or across standard business data platforms — a posture that limits external visibility into governance and decision-making structures.
What investment stages does RBV Capital target?
RBV Capital's mandate covers seed, start-up, early-stage, and expansion or late-stage venture, along with co-investment and divestiture execution. This multi-stage approach allows the firm to deploy capital across a company's full life cycle rather than concentrating on a single stage.
Does RBV Capital make direct investments or fund commitments?
The firm's strategy description indicates direct equity investing across venture stages and co-investment structures. There is no public evidence of RBV Capital operating as a fund-of-funds or allocating to third-party managers.
Which geographies does RBV Capital cover?
Headquartered in Moscow, RBV Capital is focused on the Russian market and the broader Commonwealth of Independent States region. The firm's website and public record do not indicate investment activity outside this geography.
How does RBV Capital source its deal flow?
Like many firms in the Russian venture ecosystem, RBV Capital likely relies on founder and intermediary networks within the Moscow business community. The absence of public sourcing platforms or a LinkedIn presence suggests a relationship-driven, non-institutionalized origination model.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: